Special Issue "Advances in Photodynamic Therapy 2018"
Deadline for manuscript submissions: 30 July 2018
Assoc. Prof. Dr. Michael R. Hamblin
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
Website | E-Mail
Phone: +1-617 726 6182
Fax: +1 617 726 6643
Interests: photodynamic therapy (PDT); low-level light therapy (LLLT); wound healing and infectious disease; atherosclerotic vulnerable plaque; anti-tumor immunity; photochemical mechanisms
Photodynamic therapy (PDT) is now over 100 years old, but has yet to make a big impact in modern medical practice. Nevertheless, it remains an active area of research, with constant efforts being made to develop novel, ever more-active photosensitzers, to develop active targeting strategies to better direct the photosensitizers to the tumor (or other anatomical site), to understand the photochemical mechanisms involved and improve the photochemical efficiency. In recent years a new approach called antimicrobial photodynamic inactivation has been developed, using the same principles as PDT, but this time to treat localized infections, rather than malignant tumors. Photosensitizers can be designed to be specific for microbial cells and to leave surrounding host cells unharmed. PDT has a particular ability to activate the host immune system, and in the modern age of the renaissance of immuno-oncology may have a particular role to play.Prof. Dr. Michael R. Hamblin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- photodynamic therapy
- antimicrobial photodynamic inactivation
- new photosensitizers
- anti-tumor immunity
- photosensitizer targeting
- photochemical mechanisms
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Selective Photokilling of Human Pancreatic Adenocarcinoma Cells Using EGFR Antibody-Labelled Mesoporous Silica Nanoparticles
Author: Santi Nonell
Affiliation: Institut Químic de Sarrià, Universitat Ramon Llull, Vía Augusta, 390, 08017 Barcelona, Spain
Title: Effects of blue-light-induced free radicals formation from catechin on the inactivation of Acinetobacter baumannii
Author: Ji-Yuan Liang
Abstract: In this article, we have described a finding that catechin is unstable in an alkaline solution treated with blue-light irradiation. The transformation of catechins under blue-light irradiation was investigated by chromatography and photospectrometry. Catechin dimer is formed by catechin photolysis and decreased in the presence of ascorbic acid. Detection of superoxide anion radical (O2•−) and the inactivation of Acinetobacter baumannii were examined during the photoreaction of catechin. The photochemical treatment of catechin under blue light irradiation via electron transfer generated O2•− that inactivated Acinetobacter baumannii, due primarily to reactive oxygen species (ROS) produced via photon-induced electron transfer from catechin photolysis.
Title: Clodextrins for passive targeting in cancer treatment by PDT
Author: Celine Frochot
Abstract: Photodynamic therapy (PDT) is a minimally invasive photochemical-based treatment with a promising clinical track record for oncological and some other diseases. Most PDT-drugs (photosensitizers) are highly hydrophobic and require delivery systems. To improve their solubility and pharmacokinetic properties, cyclodextrins derivatives were proposed. In this review, the use of cyclodextrins in PDT for treatment against cancer by passive targeting is described, as well as their characteristics and molecular mechanism of action when associated to photosensitizers.